APPLICATION OF ELECTRIC FIELDS TO THE LUNG AS THERAPY FOR PULMONARY EDEMA

• US 20100286746A1
• Filed: 05/04/2010
• Published: 11/11/2010
• Est. Priority Date: 05/07/2009
• Status: Active Grant

• Current Assignee: Cardiac Pacemakers Incorporated (Boston Scientific Corporation)
• Original Assignee: Cardiac Pacemakers Incorporated (Boston Scientific Corporation)
• Inventors: Wariar, Ramesh
• Granted Patent: US 8,359,093 B2
• Time in Patent Office: Days
• US Class Current: 607/42
• CPC Class Codes: A61B 5/0537 Measuring body composition by impedance, e.g. tissue hydration or fat content
• CPC Class Codes: A61B 5/415 the glands, e.g. tonsils, adenoids or thymus
• CPC Class Codes: A61B 5/418 lymph vessels, ducts or nodes
• CPC Class Codes: A61B 5/4878 Evaluating oedema
• CPC Class Codes: A61N 1/205 for promoting a biological process
• CPC Class Codes: A61N 1/32 alternating or intermittent currents applying electric fields by inductive or capacitive coupling A61N1/40; microwave apparatus A61N5/02
• CPC Class Codes: A61N 1/3601 of respiratory organs
• CPC Class Codes: A61N 1/3627 for treating a mechanical deficiency of the heart, e.g. congestive heart failure or cardiomyopathy

Abstract

System and method of applying electric fields to a patient'"'"'s lung(s) to reduce pulmonary edema. The system includes a first electrode and a second electrode, at least one of which is associated with the lung. The electric field can be controlled so as to modulate a level of fluid in the lung.

Claims

1. A system comprising:

an electric field generator circuit configured to be coupled to a first electrode and a second electrode, wherein at least one of the first electrode or the second electrode is configured to be associated with a lung of a subject, and wherein the electric field generator circuit is configured to generate an electric field, for application to the lung, that is capable of modulating a level of fluid in the lung; and

a controller coupled to the electric field generator circuit and configured to control the electric field in the lung so as to modulate the level of fluid in the lung.

2. The system of claim 1, including the at least one of the first and second electrode, and wherein the at least one of the first and second electrode is configured to be used to provide an electric field, for application to the lung, that is capable of modulating the level of fluid in the lung, and configured to be located at or near at least one of a lung, a heart, a thoracic vein, a thoracic artery, or a thoracic lymph node.

3. The system of claim 1, wherein the controller is configured to control the electric field so as to controllably effect removal of fluid from the lung.

4. The system of claim 1, wherein the controller is configured to control the electric field so as to modulate a level of fluid in the lung by modulating alveolar Na,K-ATPase activity.

5. The system of claim 1, wherein the electric field generator circuit is configured to generate an alternating electric field with field strength of about 5 microvolts/cm to about 50 millivolts/cm.

6. The system of claim 1, wherein the electric field generator circuit is configured to generate pulses at a frequency of about 1.0 MHz.

7. The system of claim 1, comprising a cardiac signal sensing circuit configured to sense an intrinsic cardiac signal, and wherein the controller is coupled to the sensing circuit and configured to determine an absolute cardiac refractory period, and wherein the controller is configured to control the electric field generator circuit to deliver pulses substantially only during the absolute cardiac refractory period.

8. The system of claim 1, comprising a fluid monitoring circuit configured to monitor a level of fluid in the lung, and wherein the controller is configured to control the electric field using information about the monitored level of fluid in the lung to control the level of fluid in the lung.

9. The system of claim 1, wherein the controller is configured to control at least one of a magnitude, a pulsewidth, a frequency, a duration, a duty cycle, or a waveform morphology associated with the electric field to control the level of fluid in the lung.

10. The system of claim 1, wherein the controller is configured to control the electric field in the lung using information from at least one implantable sensor including at least one of an implantable heart sound sensor, an implantable impedance sensor, an implantable physical activity sensor, an implantable respiration sensor, an implantable blood pressure sensor, an implantable electrocardiogram sensor, an implantable oxygen saturation sensor, an implantable blood flow sensor, or an implantable temperature sensor.

11. A system comprising:

an electric field generator circuit configured to be coupled to a first electrode and a second electrode, wherein at least one of the first electrode or the second electrode is configured to be associated with a lung of a subject, and wherein the electric field generator circuit is configured to generate an electric field, for application to the lung, that is capable of modulating a level of fluid in the lung;

a controller coupled to the electric field generator circuit and configured to control the electric field in the lung so as to modulate the level of fluid in the lung; and

a fluid monitoring circuit configured to monitor a level of fluid in the lung, and wherein the controller is configured to control the electric field using information about the monitored level of fluid in the lung to control the level of fluid in the lung.

12. The system of claim 11, including the at least one of the first and second electrode, and wherein the at least one of the first and second electrode is configured to provide an electric field located at or near at least one of a lung, a heart, a thoracic vein, a thoracic artery, or a thoracic lymph node;

wherein the controller is configured to control the electric field so as to controllably effect removal of fluid from the lung by modulating alveolar Na,K-ATPase activity;

wherein the electric field generator circuit is configured to generate an alternating electric field with field strength of about 5 microvolts/cm to about 50 millivolts/cm and a frequency of about 1.0 MHz;

wherein the controller is coupled to a cardiac signal sensing circuit, configured to sense an intrinsic cardiac signal, and wherein the controller is configured to determine an absolute cardiac refractory period, and wherein the controller is configured to control the electric field generator circuit to deliver pulses substantially only during the absolute cardiac refractory period;

wherein the controller is configured to control at least one of a magnitude, a pulsewidth, a frequency, a duration, a duty cycle, or a waveform morphology associated with the electric field to control the level of fluid in the lung; and

wherein the controller is configured to control the electric field in the lung using information from at least one implantable sensor including at least one of an implantable heart sound sensor, an implantable impedance sensor, an implantable physical activity sensor, an implantable respiration sensor, an implantable blood pressure sensor, an implantable electrocardiogram sensor, an implantable oxygen saturation sensor, an implantable blood flow sensor, or an implantable temperature sensor.

13. A method comprising:

applying an electric field to a subject using a first electrode and a second electrode, at least one of the first electrode or the second electrode being associated with a lung of the subject;

generating an electric field, for application to the lung, that is capable of modulating a level of fluid in the lung; and

controlling the electric field to modulate the level of fluid in the lung.

14. The method of claim 13, wherein applying an electric field includes using the first electrode and the second electrode in or near at least one of a lung, a heart, a thoracic vein, a thoracic artery, or a thoracic lymph node.

15. The method of claim 13, wherein controlling the electric field includes modulating alveolar Na,K-ATPase activity so as to controllably effect removal of fluid from the lung.

16. The method of claim 13, wherein applying an electric field includes providing an alternating electric field with field strength of about 5 microvolts/cm to about 50 millivolts/cm.

17. The method of claim 13, wherein the applying an electric field includes providing pulses at a frequency of about 1.0 MHz.

18. The method of claim 13, including

sensing an intrinsic cardiac signal;

determining an absolute cardiac refractory period; and

delivering electric pulses substantially only during the absolute cardiac refractory period.

19. The method of claim 13, comprising monitoring a level of fluid in the lung;

and wherein the controlling the electric field includes controlling the electric field using information about the monitored level of fluid in the lung to control the level of fluid in the lung.

20. The method of claim 13, wherein the controlling the electric field includes controlling at least one of a magnitude, a pulsewidth, a frequency, a duration, a duty cycle, or a waveform associated with the electric field to control the level of fluid in the lung.

21. The method of claim 13, wherein the controlling the electric field includes using information from at least one implantable sensor including an implantable heart sound sensor, an implantable impedance sensor, an implantable activity sensor, an implantable respiration sensor, an implantable blood pressure sensor, an implantable electrocardiogram sensor;

an implantable oxygen saturation sensor, an implantable blood flow sensor, or an implantable temperature sensor.